Can We Identify or Exclude Extensive Axillary Nodal Involvement in Breast Cancer Patients Preoperatively?
Conclusion: There is no evidence that any of the current preoperative axillary imaging modalities can accurately exclude or identify breast cancer patients with extensive nodal involvement. Both negative PET/CT and negative MRI scans (with gadolinium-based contrast agents) are promising in excluding extensive nodal involvement. Larger studies should be performed to strengthen this conclusion. False-negative rates of axillary ultrasound and ultrasound-guided needle biopsy are too high to rely on negative results of these modalities in excluding extensive nodal involvement. PMID: 31885585 [PubMed]
In conclusion, we present a plausible mechanism for the interplay between TF and IGF-1R involving FVIIa, β1-integrins, Src family proteins, and caveolin-1. Our results increase the knowledge of diseases associated with TF and IGF-1R overexpression in general but specifically of TF-mediated signaling with focus on cell survival.
In the five years after treatment, women with a history of ductal carcinoma...Read more on AuntMinnie.comRelated Reading: Who gets breast cancer treatment during a pandemic? Sentinel lymph node biopsy unnecessary for DCIS Does imaging modality influence DCIS recurrence? Preop breast MRI improves DCIS surgical planning
(Technical University of Munich (TUM)) Breast cancer is the most common cancer in women. But individual tumors can vary significantly, presenting different spatial patterns within their mass. Researchers at the Technical University of Munich (TUM) and Helmholtz Zentrum M ü nchen have now succeeded in visualizing spatial changes within tumors by means of optoacoustics. This method may be helpful for the future development of new drugs.
Publication date: Available online 24 May 2020Source: The Journal of Steroid Biochemistry and Molecular BiologyAuthor(s): Armina Kazi, Olga Goloubeva, Amanda Schech, Stephen Yu, Gauri J Sabnis
Publication date: Available online 24 May 2020Source: Inorganica Chimica ActaAuthor(s): Thankaraj Salammal Sheena, Rajakumaran Dhivya, Venkatesan Rajiu, Kulandaivel Jeganathan, Mallayan Palaniandavar, Ganesan Mathan, Mohammad Abdulkader Akbarsha
We present the application of this technology to breast cancer samples. Applying the ‘off the shelf’ cancer panel and a custom-conjugated E-cadher in antibody, we quantify vast intra-tumoural heterogeneity in immunological and tumour markers, and demonstrate a need for focussed selection of target cell populations. The technology offers enormous potential not only for making research advances but also for improving standard operating procedure s in diagnostic applications.
AbstractWe investigated time trends and factors associated with the use of cardiac imaging among women with early-stage breast cancer prior to the initiation of treatment. Of 11,732 women ages 24 –64, diagnosed with stage I–III breast cancer in 2006–2011, 2550 (22%) received anthracycline-based chemotherapy. Baseline cardiac imaging was used in 79% of patients receiving anthracyclines and increased over time. Of 2277 (20%) women who received non-anthracycline therapy, 16% received card iac imaging. Women receiving cardiac imaging in non-anthracycline therapy group were more likely to have higher cardiovas...
AbstractPurpose of ReviewBreast cancer disparities affect how different populations are impacted by breast cancer incidence, mortality, and survival. We provide an overview of large datasets that scientists can use to study disparities in breast cancer outcomes.Recent FindingsMany large datasets are accessible to disparities researchers with a project plan and little or no cost. Yet only two datasets have been significantly used in breast cancer disparities publications. Other datasets combine administrative claim, molecular, electronic health record, patient reported, imaging, and clinical trial data in a way that could b...
ye Jung Kim The key barrier to the effectiveness of radiotherapy remains the radioresistance of breast cancer cells, resulting in increased tumor recurrence and metastasis. Thus, in this study, we aimed to clarify the difference between radiotherapy-resistant (RT-R) breast cancer (BC) and BC, and accordingly, analyzed gene expression levels between radiotherapy-resistant (RT-R) MDA-MB-231 cells and MDA-MB-231 cells. Gene expression array showed that ESM-1 was the most upregulated in RT-R-MDA-MB-231 cells compared to MDA-MB-231 cells. Then, we aimed to investigate the role of ESM-1 in the increased tumorigenesis of RT-R...